Reata Pharmaceuticals (RETA) stock price, revenue, and financials

Reata Pharmaceuticals market cap is $1 b, and annual revenue was $9.02 m in FY 2020

$1 B

RETA Mkt cap, 26-May-2022

$9 M

Reata Pharmaceuticals Revenue FY, 2020
Reata Pharmaceuticals Net income (FY, 2020)-247.8 M
Reata Pharmaceuticals Cash, 31-Dec-2020818.2 M
Get notified regarding key financial metrics and revenue changes at Reata PharmaceuticalsLearn more
Banner background

Reata Pharmaceuticals Revenue Breakdown

Embed Graph

Reata Pharmaceuticals revenue breakdown by business segment: 95.3% from License and Milestone and 4.7% from Other

Reata Pharmaceuticals Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

48.1m53.6m26.5m9.0m

Revenue growth, %

(4%)12%(51%)

R&D expense

71.3m97.3m128.1m159.1m

General and administrative expense

23.3m32.7m58.3m75.1m

Operating expense total

95.0m130.5m311.7m234.2m

Depreciation and amortization

437.0k431.0k932.0k1.1m

Interest expense

1.5m6.2m11.2m

Investment income

701.0k3.5m6.2m

Pre tax profit

(47.7m)(80.5m)(290.2m)(270.2m)

Income tax expense

3.0k26.0k8.0k(22.5m)

Net Income

(47.7m)(80.5m)(290.2m)(247.8m)

EPS

(2.0)(2.9)(9.5)

Reata Pharmaceuticals Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

129.8m337.8m664.3m818.2m

Prepaid Expenses

3.3m4.5m5.0m7.0m

Current Assets

133.1m342.3m669.3m847.3m

PP&E

718.0k1.4m3.0m4.9m

Total Assets

135.3m345.2m682.4m857.6m

Accounts Payable

2.1m4.5m1.9m4.8m

Short-term debt

1.2m

Current Liabilities

47.6m55.9m192.0m119.2m

Long-term debt

18.4m79.2m155.0m

Non-Current Liabilities

234.7m274.1m233.5m321.0m

Total Debt

19.6m79.2m155.0m

Common Stock

27.0k30.0k33.0k

Additional Paid-in Capital

190.1m435.5m967.3m1.4b

Retained Earnings

(337.1m)(420.3m)(710.5m)(958.2m)

Total Equity

(147.0m)15.2m256.9m417.4m

Debt to Equity Ratio

-0.1 x5.2 x0.6 x

Debt to Assets Ratio

0.1 x0.2 x0.2 x

Financial Leverage

-0.9 x22.8 x2.7 x2.1 x

Reata Pharmaceuticals Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(47.7m)(80.5m)(290.2m)(247.8m)

Depreciation and Amortization

437.0k431.0k932.0k1.1m

Accounts Payable

(1.8m)2.0m(2.1m)2.9m

Cash From Operating Activities

(83.3m)(83.8m)(251.2m)(322.3m)

Purchases of PP&E

(344.0k)(679.0k)(2.7m)(927.0k)

Cash From Investing Activities

(343.0k)(679.0k)(2.7m)(927.0k)

Long-term Borrowings

(45.0k)

Cash From Financing Activities

128.6m292.5m580.4m477.1m

Net Change in Cash

45.0m208.0m326.5m153.8m

Interest Paid

1.2m4.7m8.2m8.0m

Reata Pharmaceuticals Ratios

USDFY, 2017

Revenue/Employee

516.8k

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-0.9 x

Reata Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

240

Patents Pending

280

Phase I Trials Products

2

Phase II Trials Products

4

Phase III Trials Products

1

Reata Pharmaceuticals Employee Rating

3.735 votes
Culture & Values
4
Work/Life Balance
4.5
Senior Management
3.9
Salary & Benefits
4.2
Career Opportunities
3.8
Source